Loading company…
ID 404433635 · FY 2017–2024 · 8 years
კომპანიის ძირითად საქმიანობას წარმოადგენს: სამედიცინო საქმიანობის ხელშეწყობა, ფარმაცევტულ პროდუქციასთან და სამედიცინო აპარატურასთან დაკავშირებული სამედიცინო და სამეცნიერო ინფორმაციის გავრცელება; საბაზრო კვლევები; სამედიცინო პროდუქციის რეგისტრაცია; კლინიკური კვლევების განვითარება; დახმარების გაწევა და სამედიცინო აპარატურით მომარაგება; სამედიცინო აპარატურის ნიმუშების იმპორტი/შეძენა და გავრცელება.
Bars are revenue on the left axis; lines are EBITDA and net margin on the right.
| Ratio | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
| Margins | ||||||||
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| EBITDA Margin | 7.1% | 7.5% | 8.0% | 8.3% | 7.9% | 7.1% | 8.0% | 7.6% |
| EBITDAR | 474 | 337 | 416 | 412 | 459 | 613 | 638 | 624 |
| EBITDAR Margin | 12.3% | 11.7% | 11.6% | 12.6% | 11.6% | 12.3% | 12.6% | 12.4% |
| EBIT Margin | 4.1% | 3.9% | 5.2% | 4.4% | 4.3% | 2.3% | 2.2% | 1.7% |
| Net Profit Margin | 5.0% | 4.9% | 5.2% | 12.2% | 5.4% | 3.1% | 5.2% | 6.7% |
| Operating Expense % of Sales | 92.9% | 92.5% | 92.0% | 91.7% | 92.1% | 92.9% | 92.0% | 92.4% |
| Returns | ||||||||
| Return on Assets (ROA) | 8.9% | 8.5% | 8.1% | 17.2% | 8.3% | 5.2% | 8.5% | 9.3% |
| Return on Equity (ROE) | 17.5% | 11.5% | 13.1% | 21.9% | 10.4% | 7.0% | 10.9% | 12.1% |
| ROIC [EBIT / Invested Capital] | 15.4% | 12.1% | 17.9% | 16.4% | 11.5% | 7.7% | 17.1% | 6.5% |
| Leverage & liquidity | ||||||||
| Debt-to-Assets | 12.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Debt-to-Equity | 0.24x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x |
| Debt-to-EBITDA | 0.95x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x |
| Equity-to-Assets | 50.8% | 74.2% | 61.7% | 78.7% | 79.7% | 74.9% | 78.1% | 76.7% |
| Net Debt | -64 | -310 | -369 | -956 | -563 | -692 | -1,795 | -1,499 |
| Cash & Equivalents | 323 | 310 | 369 | 956 | 563 | 692 | 1,795 | 1,499 |
| Total Debt | 259 | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Efficiency & working capital | ||||||||
| Inventory Turnover | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Days Inventory Outstanding (DIO) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Receivables Turnover | 2.90x | 3.07x | 2.21x | 4.69x | 5.27x | 5.76x | 77.63x | 4.39x |
| Days Sales Outstanding (DSO) | 126.0 | 118.8 | 165.4 | 77.8 | 69.3 | 63.3 | 4.7 | 83.1 |
| Payables Turnover | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Days Payable Outstanding (DPO) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash Conversion Cycle | 126.0 days | 118.8 days | 165.4 days | 77.8 days | 69.3 days | 63.3 days | 4.7 days | 83.1 days |
| Asset Turnover | 1.79x | 1.73x | 1.56x | 1.41x | 1.55x | 1.71x | 1.62x | 1.38x |
| Cash flow & dividends | ||||||||
| Operating Cash Flow | 11 | 322 | 101 | 892 | 248 | 695 | 1,394 | -274 |
| Free Cash Flow (OCF − Capex proxy) | 11 | 320 | 61 | 459 | -306 | 303 | 1,216 | -280 |
| Cash Conversion (OCF / EBITDA) | 3.9% | 149.0% | 35.0% | 328.0% | 80.0% | 196.4% | 343.9% | -71.4% |
| Dividends Declared | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividend Payout Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Money rows — EBITDAR, net debt, cash, total debt, operating and free cash flow, dividends declared — are in ₾ '000. Margins, returns and payout are percentages; turnover and leverage are multiples; DIO/DSO/DPO are days. Hover a metric name for its definition.
Shareholders, directors and group links from the companyinfo.ge public register — as filed, so stakes need not sum to 100% where a holding is undisclosed.
Ownership & directors from companyinfo.ge (public corporate registry).
Companies sharing this sub-sector, ranked by how close their latest revenue is to this one — not a curated comp set.
* Free cash flow = OCF − net investing outflow (the filings carry no standalone capex line).